Equillium (NASDAQ:EQ) versus CSL (OTCMKTS:CSLLY) Head-To-Head Review

Equillium (NASDAQ:EQ) and CSL (OTCMKTS:CSLLY) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Earnings & Valuation

This table compares Equillium and CSL”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$36.08 million	0.74	-$13.34 million	($0.14)	-5.36
CSL	$14.80 billion	6.01	$2.64 billion	N/A	N/A

CSL has higher revenue and earnings than Equillium.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Equillium and CSL, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	0	0	1	0	3.00
CSL	0	0	0	1	4.00

Equillium presently has a consensus target price of $5.00, suggesting a potential upside of 565.78%. Given Equillium’s higher possible upside, analysts plainly believe Equillium is more favorable than CSL.

Profitability

This table compares Equillium and CSL’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Equillium	-10.05%	-20.68%	-10.77%
CSL	N/A	N/A	N/A

Risk & Volatility

Equillium has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, CSL has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.

Insider and Institutional Ownership

27.1% of Equillium shares are owned by institutional investors. Comparatively, 0.0% of CSL shares are owned by institutional investors. 30.3% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

CSL beats Equillium on 8 of the 13 factors compared between the two stocks.

About Equillium

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.